Clinical Trials Logo

Filter by:
NCT ID: NCT01033019 Terminated - Clinical trials for Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

Start date: December 2009
Phase: Phase 2
Study type: Interventional

This was a double-blinded, randomized, vehicle-controlled study in sporadic superficial BCC (sBCC) and nodular BCC (nBCC) patients which consisted of a 21-day screening period, a treatment period of 6 weeks (topical 0.75% LDE225 cream application b.i.d) ending with post treatment biopsies, as safety visit one week after final study drug administration (Day 50), a visit on Day 83 for excision of the treated BCC, and an end of study evaluation (Day 90).

NCT ID: NCT01032122 Terminated - Metastatic Melanoma Clinical Trials

Rituximab in Metastatic Melanoma

Start date: October 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether rituximab as an adjuvant therapy in clinical stage IIIc / IV (no evidence of disease, AJCC (American Joint Committee on Cancer) 2002) melanoma patients is safe and prolongs overall survival and disease-free interval.

NCT ID: NCT01029795 Terminated - Clinical trials for Diabetes Mellitus, Type 2

A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus

Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to help answer the following research question(s): - To test if taking LY2599506 for 12 weeks controls blood sugar better than taking glyburide for 12 weeks. - To evaluate the safety of LY2599506 in participants with diabetes. - To determine if LY2599506 has the ability to control blood sugar in participants with diabetes. - To determine how much LY2599506 should be given to participants. - To determine if LY2599506 has an effect on a participant's weight. The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow up period.

NCT ID: NCT01026883 Terminated - Healthy Clinical Trials

Evaluation of a Novel Method for Hematocrit Level Determination

Start date: April 2010
Phase: N/A
Study type: Interventional

The hematocrit level is defined as the ratio of plasma volume and red blood cell mass. Determination of this level is important for the diagnosis and follow-up of various hematological and renal disorders. In clinical practice, automated hematology analyzers are commonly used. Recently, a new method for hematocrit level determination has been introduced which employs layered resonant piezoelectric sensors. In the present study this technique will be applied in blood samples of healthy subjects and compared to a standard laboratory method.

NCT ID: NCT01018953 Terminated - Carcinoid Syndrome Clinical Trials

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

CAMPANULA
Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of the protocol is to assess the efficacy and safety of BIM 23A760 on patient's overall satisfaction in terms of symptom relief (diarrhoea and/or flushes) in patients with carcinoid syndrome after 24 weeks of treatment.

NCT ID: NCT01009593 Terminated - Neoplasms Clinical Trials

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Start date: January 2010
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.

NCT ID: NCT01006252 Terminated - Melanoma Clinical Trials

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

SUMMIT-1
Start date: December 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study was to see how tasisulam-sodium affected metastatic melanoma when compared against paclitaxel as measured by overall survival.

NCT ID: NCT00993330 Terminated - Clinical trials for Age Related Macular Degeneration

Macular Pigment Optical Density in Healthy Subjects

Start date: May 2009
Phase: N/A
Study type: Observational

The macular pigment (MP) in humans consists of the yellow, blue-absorbing carotenoids lutein and zeaxanthin, which are contained in vegetables and fruits. The highest concentrations of lutein and zeaxanthin are found in the fovea. Since light entering the eye passes through the MP before reaching the photo receptors it absorbs a significant portion of short-wavelength light. There is evidence that these absorbing properties of the MP as well as the ability of inactivating highly reactive oxygen species are protective for the retina. Measurement of macular pigment is difficult and the investigators have recently proposed a way of measuring macular pigment optical density (MPOD) based on optical reflectometry. There is increased interest in these measurements in the recent years, because a number of studies has provided evidence that low fruit and vegetable consumption increases the risk of age related macular degeneration (AMD). The present study investigates MP optical density (OD) in healthy volunteers and is used to form a database. Furthermore the nutritional habits and the influence on MP density will be evaluated.

NCT ID: NCT00988052 Terminated - Clinical trials for Relapsing Multiple Sclerosis

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Start date: November 10, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.

NCT ID: NCT00985621 Terminated - Osteoarthritis Clinical Trials

Tanezumab In Osteoarthritis Of The Hip Or Knee

Start date: October 30, 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis